Optum Rx removes reauthorization requirements for an additional 60-plus drugs

The newly added medications include treatments for seven chronic conditions, like behavioral health, HIV, dry eye disease, high cholesterol and hypertension.

Our independent Pharmacy & Therapeutics Committee, which is guided by a clinical-first mindset and deep health care expertise to evaluate drugs based on clinical rigor and evidence, identified these additional drugs for which reauthorizations would provide minimal value. This committee, composed of practicing physicians and pharmacists, conducts unbiased, evidence-based evaluations of new and existing medications.

Optum Rx will continue to work with physicians and pharmacists to expand the list of eligible medications over time.

Since January 2025, Optum Rx has announced multiple actions aimed at transparently improving and modernizing pharmacy care, including:

• 100% pass-through of negotiated manufacturer rebates to clients
• Reimbursement to pharmacies more aligned to their acquisition costs and reduction in drug reauthorization requirements